Skip to content
OpenCapital
Get started

Protalix BioTherapeutics, Inc. PLX Q4 2024 Annual earnings

Reported March 17, 2025 · Before market open

Revenue$18.2MMiss by $3.4MDiluted EPS$0.09Beat by $0.02
Revenue estimate$21.6M
EPS estimate$0.07

Next report

Aug 13, 2026 (in a month)
Revenue estimate$13.0M
EPS estimate-$0.01

Versus estimates

Revenue

Q1 2026$33.8MBeat by $22.3MQ4 2025$9.1MMiss by $9.2MQ3 2025$17.9MBeat by $3.6MQ2 2025$15.7MBeat by $2.2MQ1 2025$10.1MMiss by $13.0M
Q4 2024$18.2MMiss by $3.4M

Diluted EPS

Q1 2026$0.22Beat by $0.23Q4 2025-$0.07Miss by $0.08Q3 2025$0.03Miss by $0.03Q2 2025$0.00Miss by $0.03Q1 2025-$0.05Miss by $0.13
Q4 2024$0.09Beat by $0.02

Ask the moment Protalix BioTherapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Protalix BioTherapeutics, Inc. report Q4 2024 earnings?
Protalix BioTherapeutics, Inc. (PLX) reported Q4 2024 earnings on March 17, 2025 before market open.
What were Protalix BioTherapeutics, Inc.'s Q4 2024 revenue and EPS?
Protalix BioTherapeutics, Inc. reported revenue of $18.2M and diluted EPS of $0.09 for Q4 2024.
Did Protalix BioTherapeutics, Inc. beat estimates in Q4 2024?
Revenue missed the consensus estimate of $21.6M by $3.4M. EPS beat the consensus estimate of $0.07 by $0.02.
Where can I find Protalix BioTherapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0001558370-25-003039) directly on SEC EDGAR. The filing index links above go to sec.gov.